Cart
sales@molnova.com
LLL3
CAS No. 63972-38-3
LLL3( LLL 3 )
Catalog No. M15430 CAS No. 63972-38-3
LLL3 is a structural analogue of STA-21 that acts as a novel STAT3 inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLLL3
-
NoteResearch use only, not for human use.
-
Brief DescriptionLLL3 is a structural analogue of STA-21 that acts as a novel STAT3 inhibitor.
-
DescriptionLLL3 is a structural analogue of STA-21 that acts as a novel STAT3 inhibitor, inhibits STAT3-dependent transcriptional and DNA binding activities; also inhibits viability of U87, U373, and U251 glioblastoma cells as well as induces apoptosis of these glioblastoma cell lines; exhibits prolonged survival in U87 glioblastoma tumour-bearing mice.
-
In Vitro——
-
In Vivo——
-
SynonymsLLL 3
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorSTAT
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number63972-38-3
-
Formula Weight266.252
-
Molecular FormulaC16H10O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(C1=C2C=CC=C1O)C3=CC=CC(C(C)=O)=C3C2=O
-
Chemical Name1-acetyl-5-hydroxyanthracene-9,10-dione
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Fuh B, et al. Br J Cancer. 2009 Jan 13;100(1):106-12.
2. Fossey SL, et al. BMC Cancer. 2009 Mar 10;9:81.
3. Mencalha AL, et al. Cancer Chemother Pharmacol. 2010 May;65(6):1039-46.
molnova catalog
related products
-
LLL-12
A nonpeptide, cell-permeable STAT3 inhibitor that binds directly to the pTyr705 binding site of the STAT3 monomer.
-
STAT3-IN-1
STAT3-IN-1 selective and orally active inhibitor of STAT3(in HT29 and MDA-MB 231 cells, with IC50 values of 1.82 μM and 2.14 μM , respectively), induces tumor apoptosis.
-
NT219
NT219 is a dual inhibitor of insulin receptor substrate 1/2 (IRS1/2) and STAT3, enhances the aggregation of misfolded prion protein NT219 affects the levels of certain molecular chaperones and inhibits STAT3 phosphorylation NT219 is useful for the study of cancer and neurodegenerative diseases.
